Skip to main content
. 2021 Aug 18;25(18):8588–8601. doi: 10.1111/jcmm.16861

TABLE 4.

Clinical studies investigating miR‐32 in patients

Sample size Origin Disease miR‐32 change References
88 Serum AMI Up REF:22
66 Serum CAC Up Liu et al. (2017)REF:6
68 OS tissues Osteosarcoma Down Lou et al. (2020)REF:52
58 Retinoblastoma and adjacent non‐tumor tissues Retinoblastoma Down Gao et al. (2020)REF:57
100 Ovarian cancer tissues and adjacent normal tissues Ovarian cancer Down Zhang et al. (2020)REF:60
34 PBMCs AML Down Wang et al. (2020a)REF:62
80 Peripheral blood ALL Up Mansouri et al. (2020)REF:65
29 Myeloid tissues Myeloma Up Sun et al. (2020b)REF:67
60 ESCC tissues ESCC Up Liu et al. (2019a)REF:17
54 Colorectal cancer tissues Colorectal cancer Up Liang et al. (2019)REF:69
28 Colorectal cancer tissues and adjacent normal tissues Colorectal cancer Up Chen et al. (2018)REF:72
80 CCa tissues and adjacent normal tissues Cervical cancer Down Liu et al. (2019b)REF:94
22 PC tissues and the adjacent normal tissues Pancreatic cancer Up Gao et al. (2017)REF:103

Abbreviations: ALL, acute lymphoblastic leukemia; AMI, acute myocardial infarction; AML, acute myeloid leukemia; CAC, coronary artery calcification; ESCC, esophageal squamous cell carcinoma; OS, osteosarcoma; PBMCs, peripheral blood mononuclear cells.